Literature DB >> 3369314

A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients?

L Thuesen1, S E Christensen, J Weeke, H Orskov, P Henningsen.   

Abstract

Cardiac function was studied by echocardiography in 12 patients with active acromegaly and in 12 age- and sex-matched healthy control subjects. None of the patients had cardiovascular diseases or other endocrine diseases than acromegaly. The patients had a mean age of 39 +/- 5 years and were short-term acromegalic with a mean duration of disease of 6 +/- 3 years. Mean left ventricular mass was 163 +/- 43 g/m2 in the acromegalic group versus 120 +/- 24 g/m2 in the control group. Preload (the diastolic diameter of the left ventricle) was within normal limits, while afterload (end-systolic meridional wall stress) was significantly decreased in the acromegalic group. Myocardial contractility assessed as fractional shortening of the left ventricle was 39.9 +/- 3.6% in the acromegalic group versus 32.9 +/- 5.1% in the control group, and cardiac output was increased by 52% in the acromegalic group because of increased heart rate and stroke volume. We suggest that augmented peripheral blood flow is responsible for the condition of cardiac hyperkinesia in short-term acromegaly and involved in the development of hypertension, which is a frequent complication of long-term acromegaly.

Entities:  

Mesh:

Year:  1988        PMID: 3369314     DOI: 10.1111/j.0954-6820.1988.tb15882.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  15 in total

1.  Doppler echocardiographic patterns in patients with acromegaly.

Authors:  M Terzolo; L Avonto; C Matrella; R Pozzi; S Luceri; G Borretta; F Pecchio; G Ugliengo; G P Magro; G Reimondo
Journal:  J Endocrinol Invest       Date:  1995-09       Impact factor: 4.256

2.  Localization of growth hormone receptor messenger RNA in human tissues.

Authors:  H C Mertani; M C Delehaye-Zervas; J F Martini; M C Postel-Vinay; G Morel
Journal:  Endocrine       Date:  1995-02       Impact factor: 3.633

Review 3.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides.

Authors:  Mikkel Andreassen; Jens Faber; Andreas Kjær; Claus Leth Petersen; Lars Østergaard Kristensen
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

5.  The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.

Authors:  Laura De Marinis; Antonio Bianchi; Gherardo Mazziotti; Marco Mettimano; Domenico Milardi; Alessandra Fusco; Vincenzo Cimino; Giulio Maira; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

6.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

7.  Cardiovascular effects of high-dose growth hormone treatment in growth hormone-deficient children.

Authors:  R Crepaz; W Pitscheider; G Radetti; C Paganini; L Gentili; G Morini; E Braito; G Mengarda
Journal:  Pediatr Cardiol       Date:  1995 Sep-Oct       Impact factor: 1.655

Review 8.  Acromegalic cardiomyopathy: a review of the literature.

Authors:  M P Matta; P Caron
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

9.  Assessment of cardiac autonomic functions by heart rate recovery, heart rate variability and QT dynamicity parameters in patients with acromegaly.

Authors:  Muhammet Dural; Giray Kabakcı; Neşe Cınar; Tomris Erbaş; Uğur Canpolat; Kadri Murat Gürses; Lale Tokgözoğlu; Ali Oto; Ergün Barış Kaya; Hikmet Yorgun; Levent Sahiner; Selçuk Dağdelen; Kudret Aytemir
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

10.  Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD).

Authors:  A I Pincelli; R Bragato; M Scacchi; G Branzi; G Osculati; R Viarengo; G Leonetti; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.